Literature DB >> 17702832

Levosimendan in septic shock: a case series.

B P Powell, B L De Keulenaer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17702832     DOI： 10.1093/bja/aem225

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN： 0007-0912            Impact factor:   9.166


× No keyword cloud information.
  5 in total

1.  Levosimendan for resuscitating the microcirculation in patients with septic shock: a randomized controlled study.

Authors:  Andrea Morelli; Abele Donati; Christian Ertmer; Sebastian Rehberg; Matthias Lange; Alessandra Orecchioni; Valeria Cecchini; Giovanni Landoni; Paolo Pelaia; Paolo Pietropaoli; Hugo Van Aken; Jean-Louis Teboul; Can Ince; Martin Westphal
Journal:  Crit Care       Date:  2010-12-23       Impact factor: 9.097

Review 2.  Sepsis-induced cardiomyopathy.

Authors:  Francisco J Romero-Bermejo; Manuel Ruiz-Bailen; Julian Gil-Cebrian; Maria J Huertos-Ranchal
Journal:  Curr Cardiol Rev       Date:  2011-08

3.  Levosimendan inhibits release of reactive oxygen species in polymorphonuclear leukocytes in vitro and in patients with acute heart failure and septic shock: a prospective observational study.

Authors:  Julia Hasslacher; Klaudija Bijuklic; Cristina Bertocchi; Jordan Kountchev; Romuald Bellmann; Stefan Dunzendorfer; Michael Joannidis
Journal:  Crit Care       Date:  2011-07-12       Impact factor: 9.097

4.  Decatecholaminization and calcium sensitizers in critically ill patients.

Authors:  Samad E J Golzari; Ata Mahmoodpoor
Journal:  Res Cardiovasc Med       Date:  2014-02-24

5.  An efficacy and mechanism evaluation study of Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis (LeoPARDS): protocol for a randomized controlled trial.

Authors:  Robert M L'E Orme; Gavin D Perkins; Daniel F McAuley; Kathleen D Liu; Alexina J Mason; Andrea Morelli; Mervyn Singer; Deborah Ashby; Anthony C Gordon
Journal:  Trials       Date:  2014-06-02       Impact factor: 2.279
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.